C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2026)
C4 Therapeutics has reported Depreciation and Depletion over the past 7 years, most recently at $360000.0 for Q1 2026.
- For Q1 2026, Depreciation and Depletion fell 1.1% year-over-year to $360000.0; the TTM value through Mar 2026 reached $1.5 million, up 10.66%, while the annual FY2025 figure was $1.5 million, 4.62% up from the prior year.
- Depreciation and Depletion for Q1 2026 was $360000.0 at C4 Therapeutics, down from $377000.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $521000.0 in Q4 2022 and troughed at $128000.0 in Q4 2023.
- A 5-year average of $382647.1 and a median of $377000.0 in 2025 define the central range for Depreciation and Depletion.
- Biggest five-year swings in Depreciation and Depletion: plummeted 75.43% in 2023 and later surged 184.38% in 2024.
- Year by year, Depreciation and Depletion stood at $521000.0 in 2022, then plummeted by 75.43% to $128000.0 in 2023, then surged by 184.38% to $364000.0 in 2024, then grew by 3.57% to $377000.0 in 2025, then decreased by 4.51% to $360000.0 in 2026.
- Business Quant data shows Depreciation and Depletion for CCCC at $360000.0 in Q1 2026, $377000.0 in Q4 2025, and $384000.0 in Q3 2025.